NeuroPace (NPCE) IPO Opens 37% Higher

Today's IPO for NeuroPace, Inc. (NASDAQ: NPCE) opened for trading at $23.25 after pricing 6,000,000 shares of common stock at a public offering price of $17.00 per share.

J.P. Morgan and Morgan Stanley are acting as joint lead book-running managers for the offering. Wells Fargo Securities and SVB Leerink are also acting as book-running managers for the offering.

Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients suffering from drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

You May Also Be Interested In

• SpaceX prices IPO at $135 per share for June 12 Nasdaq debut
• AES prices $1 billion senior notes offering with 2029 and 2033 maturities
• SpaceX Registration Statement Declared Effective On June 11